{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000108","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.735779+00:00","generated_at":"2026-05-17T07:19:18.258534+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial","bullets":["Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.","Convertible at $5.18/share (9/8 close), 10% annual interest payable quarterly after first year, 5-yr maturity.","Each tranche carries 100% warrant coverage at $5.44/share; warrants expire 60 days after first Cohort 2 dose or Sept 30, 2026.","Proceeds to advance SER-252 Phase 1b registrational trial for advanced Parkinson's under 505(b)(2) NDA path.","IND submission planned Q4 2025; dosing in Australia Q4 2025 and U.S. initiation Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000108","json":"https://secwatch.observer/filing/0001708599-25-000108.json","markdown":"https://secwatch.observer/filing/0001708599-25-000108.md","text":"https://secwatch.observer/filing/0001708599-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000108/0001708599-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000108/ser-20250909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:19:18.258534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}